Abstract
Background: In the 1990s, the beta interferons and glatiramer acetate were introduced for treating relapsing-remitting multiple sclerosis. These medications have a demonstrated record of efficacy and safety, although they require frequent administration via injection and are only partially effective. The optimization of treatment in patients who do not respond adequately to this first-line therapy is essential for attaining the best long-term outcomes. Switching to the recently approved emergent therapies is a strategy to consider for treatment of patients with a suboptimal response.
Objective: This review summarizes the mechanisms of action, clinical benefits, and safety profiles of current multiple sclerosis disease-modifying therapies, including highly efficacious monoclonal antibodies or convenient oral therapies, and with a special focus on the pegylated interferon beta 1a formulation.
Methods: We reviewed the recent literature and human clinical trials on multiple sclerosis therapies by bibliographic search in PubMed and clinicaltrials.gov.
Results and Conclusion: Although the first-line interferon beta exhibits a favorable benefit-torisk profile, treatment compliance is compromised potentially due to its known adverse events and frequent injectable administration. Less frequent dosing and improved pharmacological properties have been achieved by reaction of interferon beta with chemically activated polyethylene glycol. Provided that none of the available therapies show better effectiveness for all outcomes and their safety in clinical practice is of a fundamental concern, the pegylated form of interferon beta seems to keep its place as a competitive therapeutic option.
Keywords: Pegylated interferon beta, PEG-IFN-β, multiple sclerosis, emergent therapies, treatment strategies, therapy optimization, management of MS patients.
Current Medicinal Chemistry
Title:New Life to an Old Treatment: Pegylated Interferon Beta 1a in the Management of Multiple Sclerosis
Volume: 25 Issue: 27
Author(s): Miguel Angel Ortiz*, Laura Espino-Paisan*, Concepcion Nunez, Roberto Alvarez-Lafuente and Elena Urcelay
Affiliation:
- Red Espanola de Esclerosis Multiple (REEM), Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Ministerios de Economia y Competitividad, Madrid,Spain
- Red Espanola de Esclerosis Multiple (REEM), Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Ministerios de Economia y Competitividad, Madrid,Spain
Keywords: Pegylated interferon beta, PEG-IFN-β, multiple sclerosis, emergent therapies, treatment strategies, therapy optimization, management of MS patients.
Abstract: Background: In the 1990s, the beta interferons and glatiramer acetate were introduced for treating relapsing-remitting multiple sclerosis. These medications have a demonstrated record of efficacy and safety, although they require frequent administration via injection and are only partially effective. The optimization of treatment in patients who do not respond adequately to this first-line therapy is essential for attaining the best long-term outcomes. Switching to the recently approved emergent therapies is a strategy to consider for treatment of patients with a suboptimal response.
Objective: This review summarizes the mechanisms of action, clinical benefits, and safety profiles of current multiple sclerosis disease-modifying therapies, including highly efficacious monoclonal antibodies or convenient oral therapies, and with a special focus on the pegylated interferon beta 1a formulation.
Methods: We reviewed the recent literature and human clinical trials on multiple sclerosis therapies by bibliographic search in PubMed and clinicaltrials.gov.
Results and Conclusion: Although the first-line interferon beta exhibits a favorable benefit-torisk profile, treatment compliance is compromised potentially due to its known adverse events and frequent injectable administration. Less frequent dosing and improved pharmacological properties have been achieved by reaction of interferon beta with chemically activated polyethylene glycol. Provided that none of the available therapies show better effectiveness for all outcomes and their safety in clinical practice is of a fundamental concern, the pegylated form of interferon beta seems to keep its place as a competitive therapeutic option.
Export Options
About this article
Cite this article as:
Ortiz Angel Miguel*, Espino-Paisan Laura*, Nunez Concepcion, Alvarez-Lafuente Roberto and Urcelay Elena, New Life to an Old Treatment: Pegylated Interferon Beta 1a in the Management of Multiple Sclerosis, Current Medicinal Chemistry 2018; 25 (27) . https://dx.doi.org/10.2174/0929867325666180226105612
DOI https://dx.doi.org/10.2174/0929867325666180226105612 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preliminary Evaluation of Anticonvulsant Activity of Some Aminoalkanol and Amino Acid Cinnamic Acid Derivatives
Letters in Drug Design & Discovery Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Editorial [Hot-Topic: Anti-inflammatory and Anti-Allergy Functions of Capsaicin in Association with its Actions on Primary Sensory Neurons (Guest Editor: Akio Hiura & Gabor Jancso)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Topical Analgesics in Neuropathic Pain
Current Pharmaceutical Design The Chemokine System as a Therapeutic Target in Autoimmune Thyroid Diseases: A Focus on the Interferon-γ Inducible Chemokines and their Receptor
Current Pharmaceutical Design Role of Vitamin D in Vascular Complications and Vascular Access Outcome in Patients with Chronic Kidney Disease
Current Medicinal Chemistry Structure-Based Design in the GPCR Target Space
Current Medicinal Chemistry Surrogates of Insulin Sensitivity and Indices of Cardiometabolic Profile in Obesity
Current Vascular Pharmacology Anticoagulant and Fibrinolytic Drugs – Possible Agents in Treatment of Lung Cancer?
Anti-Cancer Agents in Medicinal Chemistry Terpenoids: Sources, Structure Elucidation and Therapeutic Potential in Inflammation
Current Topics in Medicinal Chemistry Small Molecule Antagonists of Integrin Receptors
Current Medicinal Chemistry Anti-Biofilm Strategies and the Need for Innovations in Wound Care
Recent Patents on Anti-Infective Drug Discovery Chitosan Formulations as Carriers for Therapeutic Proteins
Current Drug Discovery Technologies Stem Cell Engineering for the Treatment of Severe Hemoglobinopathies
Current Molecular Medicine Interferon-γ-Induced Conversion of Tryptophan: Immunologic and Neuropsychiatric Aspects
Current Medicinal Chemistry There is a Link Between Erectile Dysfunction and Heart Failure: It could be Inflammation
Current Drug Targets Graft-Versus-Host Disease: A Model of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Current Immunology Reviews (Discontinued) Immobilization-Induced Behavioral Deficits are Attenuated But Coping with Repeated Stress Impaired in Apomorphine Injected Rats
Current Psychopharmacology Biodiversity as a Source of Bioactive Compounds Against Snakebites
Current Medicinal Chemistry Transcriptional Regulation by Promoter Targeted RNAs
Current Topics in Medicinal Chemistry